Our policy in the Medical Programs Department of the National Psoriasis Foundation (NPF) is to ensure balance, independence, objectivity, and scientific rigor in all our educational programs.  Anyone presenting or participating in the planning of any NPF CME programs is expected to disclose to the Medical Programs Department any real or apparent affiliation(s) within the past 12 months that may have a direct bearing on the subject matter of the continuing medical education program.  The intent of this policy is to ensure continuing medical education programs that are free of commercial interests.

The following faculty and planning committee have disclosed the following relationships with commercial interests:

Faculty:

Mark Lebwohl, MD 

Chair, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
 

Dr. Lebwohl has disclosed the following relevant financial relationships: 
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Janssen Research & Development, LLC; Kadmon Corporation, LLC; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; Vidac

Joel Gelfand, MD 

Professor and Vice-Chair, Dermatology and Epidemiology; Vice-Chair of Clinical Research; Director of Psoriasis and Phototherapy Treatment Center, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
 

Dr. Gelfand has disclosed the following relevant financial relationships: 
Served as an advisor or consultant for: Coherus Biosciences; Dermira Inc.; Dr. Reddy's Laboratories Ltd.; Janssen Pharmaceuticals, Inc.; Menlo Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Lilly
Received grants for clinical research from: AbbVie Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi 
Other: Co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma

Jeffrey Weinberg, MD
Associate Clinical Professor, Dermatology at Mount Sinai St. Luke's, West, and Beth Israel Medical Center, New York, New York

Dr. Weinberg has disclosed the following relevant financial relationships: 
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Celgene Corporation; LEO Pharma Inc.; Lilly; Valeant Pharmaceuticals International 
Received grants for clinical research from: AbbVie Inc.; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation

Planning Committee:
Andi Agnew has no relevant financial interests with any commercial interests.